ShareValue scores for 688217.SHG: Valuation 54, Quality 40, Growth 40, Health 54.

688217.SHG
SSE

Shanghai Rightongene Biotechnology Co. Ltd. A

CN¥23.19(+4.70%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 16%
Valuation
54
Fair Value
Price vs Value
Quality
40
Moderate
Business Strength
Growth
40
Weak
Revenue & Earnings
Health
54
Moderate
Financial Stability
Momentum
33
Bearish
Price Trend

Company Details

About

Shanghai Rightongene Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products. The company provides gene and antigen testing for patients; and offers treatment plans, such as disease diagnosis, risk assessment, disease classification, targeted drug selection, and efficacy monitoring for for initial screening, follow-up, and re-examination of leukemia patients. It also offers molecular diagnostic kits for genes related to leukemia, lymphoma, solid tumors, and infectious diseases. In addition, it provides third-party medical testing services to various medical institutions, pharmaceutical companies, and individual patients, as well as gene testing research services to research hospitals, pharmaceutical companies, research institutions, and other third-party testing organizations. Shanghai Rightongene Biotechnology Co., Ltd. was founded in 2012 and is based in Shanghai, China.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026